Optimal biannual COVID-19 vaccine boosting dates for those aged 65 and over
Townsend, J. P.; Hassler, H.; Dornburg, A.
Show abstract
BackgroundTo mitigate transmission and reduce the morbidity and mortality, the CDC recommends that individuals aged 65 and older receive a second dose of the 2024-2025 COVID-19 vaccine six months after their first booster dose. However, the optimal dates for biannual boosting are unknown. Geographic variation in infection rates throughout the year make it challenging to intuit the best yearly booster administration date to effectively prevent infection. With rapid waning and strong peaks associated with seasonality, precise timing of booster administration can maximize clinical and public health benefits. MethodsWe integrated longitudinal antibody waning trajectories, reinfection probabilities, and spatiotemporal projections of COVID-19 incidence to construct a geographically resolved model for optimizing booster timing in adults aged 65 and older. ResultsThe benefit of dual booster vaccination is substantially increased by optimal timing, conferring as much as a 3-4-fold decrease in infection risk over five years. This benefit depends not only on the date of initial vaccination but also on the date of the second boost, which often falls outside of the current 6 month recommendation. In New York, for instance, optimal biannual booster dates are September 21 and February 22. In general, they are location-specific, relating to the geography of seasonal incidence. ConclusionsSubstantial benefit accrues from aptly timing dual COVID-19 booster vaccination campaigns for individuals over 65. Booster vaccination should be tailored to specific locations and anticipate regional periods of peak transmission. Analyses provide location-specific guidance for public health policy, healthcare provider recommendations, and individual decision-making. SummaryOptimal timing for COVID-19 boosters improves their efficacy. Our analysis enables beneficial personalization of biannual booster schedules on the basis of infection history. This personalization improves public health. Key pointsO_LIOptimal biannual COVID-19 booster vaccination dates are in early autumn and late spring in most of the Northern Hemisphere. C_LIO_LIOptimal intervals between biannual boosts range from 4-7 months depending on location. C_LIO_LIBiannual boosting on the optimal dates provides up to 3-4 fold more protection. C_LIO_LIDelayed initial vaccination substantially alters the optimal second boost date. C_LI
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination 95%
- Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics 94%
- Optimal age targeting for pneumococcal vaccination in older adults; a modelling study 94%
Similar papers in this journal
- Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study 93%
- Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan 93%
- The impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: a modeling study 92%
Similar papers in this journal
- The impact of vaccination on COVID-19 outbreaks in the United States 94%
- Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults 93%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 93%
Similar papers in this journal
- Waning of two-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection is robust to depletion-of-susceptibles bias 94%
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel 93%
- The long-term success of mandatory vaccination laws at implementing the first vaccination campaign in 19 th century rural Finland 92%
Similar papers in this journal
- Post-vaccine HAI antibody kinetics are driven by pre-vaccination HAI titre and vaccine history 94%
- Cost-effectiveness of routine COVID-19 adult vaccination programmes in England 94%
- Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.